Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2010 Oct;126(4):674-81.
doi: 10.1542/peds.2009-3348. Epub 2010 Sep 20.

Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Schönlein purpura

Pamela F Weiss  1 , Andrew J Klink, Russell Localio, Matt Hall, Kari Hexem, Jon M Burnham, Ron Keren, Chris Feudtner
Affiliations
Multicenter Study

Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Schönlein purpura

Pamela F Weiss et al. Pediatrics. 2010 Oct.

Abstract

Objective: To characterize the effect of corticosteroid exposure on clinical outcomes in children hospitalized with new-onset Henoch-Schönlein purpura (HSP).

Patients and methods: We conducted a retrospective cohort study of children discharged with an International Classification of Diseases, Clinical Modification code of HSP between 2000 and 2007 by using inpatient administrative data from 36 tertiary care children's hospitals. We used stratified Cox proportional hazards regression models to estimate the relative effect of time-varying corticosteroid exposure on the risks of clinical outcomes that occur during hospitalization for acute HSP.

Results: During the 8-year study period, there were 1895 hospitalizations for new-onset HSP. After multivariable regression modeling adjustment, early corticosteroid exposure significantly reduced the hazard ratios for abdominal surgery (0.39 [95% confidence interval (CI): 0.17-0.91]), endoscopy (0.27 [95% CI: 0.13-0.55]), and abdominal imaging (0.50 [95% CI: 0.29-0.88]) during hospitalization.

Conclusions: In the hospital setting, early corticosteroid exposure was associated with benefits for several clinically relevant HSP outcomes, specifically those related to the gastrointestinal manifestations of the disease.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Corticosteroid use and early-period resource utilization. Corticosteroid use was defined as initial exposure to corticosteroids on day 1 or 2 of hospitalization. Hospital charges on days 1 to 2 are used as a proxy for admission severity. Hospital charges were log-transformed and then normalized for admitting hospital. CS indicates corticosteroids.
FIGURE 2
FIGURE 2
Clinical outcomes in corticosteroid-exposed and -unexposed subjects. Only the first 10 days of hospitalization are graphically represented, because 10 days was the 95th percentile for length of initial hospitalization. A, Surgery; B, endoscopy; C, parenteral nutrition; D, abdominal imaging. CS indicates corticosteroids; early CS, initial corticosteroid exposure on hospital day 1 or 2.
FIGURE 3
FIGURE 3
Initiation of NSAIDs (A), opioids (B), and antihypertensive agents (C) in corticosteroid-exposed and -unexposed subjects. Only the first 10 days of hospitalization are graphically represented, because 10 days was the 95th percentile for length of initial hospitalization. CS indicates corticosteroids; early CS, initial corticosteroid exposure on hospital day 1 or 2.
See this image and copyright information in PMC

References

    1. Bowyer S, Roettcher P. Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. Pediatric Rheumatology Database Research Group. J Rheumatol. 1996;23(11):1968–1974. - PubMed
    1. Rostoker G. Schönlein-Henoch purpura in children and adults: diagnosis, pathophysiology and management. BioDrugs. 2001;15(2):99–138. - PubMed
    1. Ronkainen J, Koskimies O, Ala-Houhala M, et al. Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2006;149(2):241–247. - PubMed
    1. Reinehr T, Burk G, Berger T, Doeker B, Andler W. Steroids for prophylaxis of nephropathy in Schnlein Henoch purpura? Follow-up of 171 patients [in German] Klin Padiatr. 2000;212(3):99–102. - PubMed
    1. Huber AM, King J, McLaine P, Klassen T, Pothos M. A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein purpura [ISRCTN85109383] BMC Med. 2004;2:7. - PMC - PubMed

Publication types

LinkOut - more resources